Based on the provided financial report articles, I generated the title for the article: **"Quarterly Financial Report for Q2 2026: [Company Name]"** Please note that the title may not be exact, as the provided text does not contain the company name.
Based on the provided financial report articles, I generated the title for the article: **"Quarterly Financial Report for Q2 2026: [Company Name]"** Please note that the title may not be exact, as the provided text does not contain the company name.
Unfortunately, the provided text does not appear to be a financial report, but rather a collection of data points and financial statements. However, I can try to summarize the key financial figures and main events mentioned in the text.
The text appears to be a compilation of various financial statements, including balance sheets and income statements, for a company with the ticker symbol 0001533743. The statements cover the periods from January 1, 2025, to June 30, 2026, and include information on common stock, additional paid-in capital, treasury stock, and retained earnings.
Some key financial figures mentioned in the text include:
- Common stock: The number of shares outstanding and the par value per share.
- Additional paid-in capital: The amount of capital contributed by shareholders beyond the par value of the common stock.
- Treasury stock: The number of shares repurchased by the company and held in treasury.
- Retained earnings: The company’s accumulated profits and losses.
The text also mentions various dates, including the filing date of the financial statements (August 7, 2026) and the dates of the company’s fiscal years (January 1, 2025, to December 31, 2025, and January 1, 2026, to June 30, 2026).
Unfortunately, without more context and analysis, it is difficult to provide a more detailed summary of the financial report. If you have any specific questions or would like me to help you analyze the data, please let me know.
Overview
Processa Pharmaceuticals, Inc. is a clinical-stage biotechnology company that recently acquired Vidya Therapeutics, Inc. and its lead asset VT-7208, a Bruton’s tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases. The company is also continuing the development of its legacy pharmaceutical assets, including PCS499, PCS12852, and PCS11T.
Recent Developments
Vidya Acquisition: In July 2026, Processa acquired Vidya Therapeutics and received $200 million in gross proceeds from a private placement financing to fund operations and advance VT-7208 through key clinical milestones.
Elion Settlement Agreement: Processa entered into a settlement agreement with Elion Oncology to resolve all claims related to the PCS6422 program, which was returned to Elion. Processa paid Elion $650,000 and agreed to grant Elion a non-voting equity interest in any newly formed entity that includes PCS499, PCS12852, or PCS11T.
Other 2026 Fundraising: Processa raised additional funds through private placements, stock sales, and an ATM offering, totaling approximately $560,000.
Our Drug Pipeline
Processa’s drug pipeline includes the following assets:
| Asset | Indication |
|---|---|
| VT-7208 | Food allergy, Chronic spontaneous urticaria (CSU), Relapsing multiple sclerosis (RMS) |
| PCS499 | - |
| PCS12852 | - |
| PCS11T | - |
Results of Operations
Processa reported the following financial results:
| Metric | Three Months Ended June 30 | Six Months Ended June 30 | ||||
|---|---|---|---|---|---|---|
| 2026 | 2025 | Change | 2026 | 2025 | Change | |
| Operating Expenses | ||||||
| Research and development | $649,877 | $2,447,286 | $(1,797,409) | $2,459,041 | $4,035,767 | $(1,576,726) |
| General and administrative | $1,686,261 | $1,503,497 | $182,764 | $3,208,311 | $2,762,006 | $446,305 |
| Operating Loss | $(2,336,138) | $(3,950,783) | - | $(5,667,352) | $(6,797,773) | - |
| Other Income (Expense), net | $(929,356) | $16,865 | $(946,221) | $(975,321) | $29,450 | $(1,004,771) |
| Net Loss | $(3,265,494) | $(3,933,918) | - | $(6,642,673) | $(6,768,323) | - |
The decrease in research and development expenses was primarily due to a decrease in costs related to the NGC-Cap Phase 2 trial, which was placed on hold for an interim analysis. General and administrative expenses increased due to higher professional fees, insurance, and other expenses.
Cash Flows
| Cash Flow Metric | Six Months Ended June 30 | |
|---|---|---|
| 2026 | 2025 | |
| Net cash used in operating activities | $(5,586,580) | $(5,000,253) |
| Net cash used in investing activities | $(314,000) | $- |
| Net cash provided by financing activities | $559,950 | $10,745,548 |
| Net (decrease) increase in cash | $(5,340,630) | $5,745,295 |
The increase in cash used in operating activities was primarily due to higher professional, consulting, insurance, payroll, and travel-related expenses. Investing activities included the purchase and sale of digital assets, while financing activities included the sale of common stock and the exercise of warrants.
Liquidity
Following the Vidya acquisition and $200 million private placement, Processa believes its cash and cash equivalents will be sufficient to satisfy its cash requirements over the next 12 months and beyond. This represents a material change from the substantial doubt about the company’s ability to continue as a going concern reported in its 2025 Form 10-K.
Processa will continue to be dependent on equity and/or debt financing until it is able to generate positive cash flows from operations. The company plans to raise additional funds through a combination of public or private equity offerings, debt financings, collaborations, and other arrangements, but will only do so if the terms are acceptable.